Who we are
Access Accelerated (AA) is a unique cross-industry collaboration that seeks to reduce barriers to prevention, treatment and care for NCDs in lower- and middle-income countries through health systems strengthening and alignment with Universal Health Coverage objectives and priorities. For the first time, 24 global biopharmaceutical companies have come together to bring their global reach and local expertise in partnership with countries, civil society, multilaterals and NGOs to support cross-sectoral dialogue and drive on-the-ground implementation and action plans to address NCDs.
AA works towards a future where no one dies prematurely from treatable, preventable diseases and all people living with or at risk of NCDs have access to appropriate, quality, and affordable prevention, treatment and care. AA recognizes that only by putting the needs of people living with NCDs first and acting in collaboration with governments, civil society, multilaterals, NGOs and others can the global community make measurable and sustainable progress against NCDs in developing countries.
How do we get there?
Access Accelerated is committed to helping to achieve the United Nations Sustainable Development Goals and the target to reduce premature deaths from NCDs by one-third by 2030 and seeks to lead private sector engagement in driving access to NCD prevention, treatment and care for people living with NCDs around the world. We believe that:
- NCDs are an urgent public health challenge
- The private sector – particularly, the pharmaceutical industry – has a critical role to play in facilitating access to NCD care
- Access Accelerated is stronger than the sum of its parts and is an impact-focused, holistic private sector contribution to the global effort on NCDs